The preliminary/preclinical success of the aforementionedmultitargetingagents strengthened our concievement to extract anti-GBM potentialthrough logical stitching of the EZH2 inhibitory template with mechanisticallydiverse antitumor pharmacophores. The gene discussed is EZH2; the disease is glioblastoma.